Name:
Professor Sarah Blagden
Job Title
Professor of Experimental Oncology
Organisation / Company:
University of Oxford
Biography:
Following medical training, Sarah undertook subsequent specialist training in Medical Oncology at Addenbrooke’s Hospital in Cambridge and the Royal Marsden Hospital, London. Sarah was awarded a CRUK Junior Clinician Scientist PhD fellowship to study fruit fly genetics at Cambridge University (2000-2004) and later held a Clinical Fellowship at the Institute of Cancer Research’s Drug Development Unit.
She was appointed as Senior Lecturer and Honorary Consultant at Imperial College in 2006 where she specialised in treating gynaecological cancers, launched Imperial’s Early Phase Trial portfolio and established her laboratory studying the dysregulation of mRNA translation in cancer. In 2015 she moved to Oxford University and is now a Professor of Experimental Oncology. Sarah was Director of the Early Phase Clinical Trials Unit until 2021 when she took over leadership of the Oxford Clinical Trials Office (OCTO) running a national trials portfolio specialising in early phase, Precision Prevention and Early Detection studies. She has been chief or principal investigator for a number of national and international clinical studies and her team’s research focus is post-transcriptional gene regulation in precancer progression.